CytoDyn Inc.

  • Home
  • About CytoDyn
    • Overview
    • Our Mission
  • Our Science
  • Pipeline
  • Our Team
    • Leadership Team
    • Scientific Advisory Board
    • Board of Directors
    • Join our Team
  • Publications & Posters
  • Newsroom
  • Investors
    • Overview
    • Investor FAQs
    • Investor Update Calls
    • Annual Meeting of Stockholders
    • Warrant Exercise Inquiries
    • Restricted Stock Inquiries
    • News / Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Newsroom

  • All
  • Press Release
  • Video

CytoDyn Releases ESMO Breast Cancer Meeting Poster

May 15, 2025 8:30am EDT
Press Release

CytoDyn Announces Data Suggesting Novel Mechanism of Action of Leronlimab for the Treatment of Solid Tumors

May 13, 2025 8:30am EDT
Press Release

CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer

May 06, 2025 8:30am EDT
Press Release

CytoDyn Leadership Team To Attend ESMO Breast Cancer Meeting in Munich, Germany

Apr 29, 2025 8:30am EDT
Press Release

March 2025 Letter to Shareholders

Mar 18, 2025 8:30am EDT
Press Release

CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab

Feb 24, 2025 8:30am EST
Press Release

CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories

Feb 06, 2025 8:30am EST
Press Release

December 2024 Letter to Shareholders

Dec 17, 2024 8:30am EST
Press Release

CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology

Nov 25, 2024 8:30am EST
Press Release

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

Nov 04, 2024 8:30am EST
Press Release
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    Next
    © 2025 CytoDyn Inc. All Rights Reserved.
    Privacy Policy Legal Notice & Disclaimer Forward-Looking Statement Disclosure Sitemap